Gayyata a yau ta sanar da cikakkiyar damar zuwa dandalin sa na Kula da Ciwon Kankara (PCMTM) don taimakawa gano ƙarancin cuta ko saura kwayoyin cuta (MRD) a cikin marasa lafiya masu ƙarfi. Invitae PCM yana amfani da sabon saitin kididdigar keɓancewar mutum dangane da ƙwayar majiyyaci don gano ƙwayar ƙwayar cuta ta DNA (ctDNA) a cikin jini, tana ba da ikon aiwatar da haɗarin haɗari, ƙimar amsawa ga jiyya da gano sake dawowar cutar kansa, dangane da binciken kwanan nan.

"Rikicin haɗarin sake dawowa shine buƙatar asibiti ga yawancin marasa lafiya da ke fama da jiyya ga ciwace-ciwacen ƙwayoyi kuma an fi amfani da su ta hanyar kayan aikin kwayoyin halitta na yau da kullum don dacewa da ingantawa akan ma'auni na hanyoyin kulawa don gano sake dawowa," in ji Robert Nussbaum, MD, shugaba. likita, Gayyata. "Tsarin PCM ya dace da hanyoyin sa ido na yanzu, kuma yana da ikon tantance tasirin maganin ciwon daji a baya fiye da waɗancan hanyoyin ga marasa lafiya da yawa, yana bawa likitocin damar damar daidaita zaɓuɓɓukan magani."

A cikin shekaru da yawa da suka gabata, bincike daga Invitae da manyan al'ummar kimiyya, ciki har da binciken TRACERx wanda Farfesa Charles Swanton ya jagoranta a Cibiyar Francis Crick da Kwalejin Jami'ar London (UCL), kuma Cibiyar Nazarin Ciwon daji ta Burtaniya ta ba da tallafi, ya nuna cewa saka idanu na MRD zai iya. amintacce gano masu cutar kansar huhu a cikin babban haɗarin sake dawowa, gano sake dawowa bayan tiyata sau da yawa fiye da daidaitaccen hoto, tantance martanin jiyya, da yuwuwar yin aiki azaman madogara don ƙarshen gwajin gwaji na asibiti. Tare da waɗannan iyawar, saka idanu na MRD yayi alƙawarin gajarta gwajin asibiti da haɓaka haɓaka sabbin magunguna masu yuwuwar ceton rai. Invitae PCM shine maganin ciwon daji, sanin ƙari-sanarwar ruwa biopsy kima, haɗin gwiwa tare da haɗin gwiwar TRACERx, wanda ke amfani da jerin tsararraki na gaba (NGS) don nazarin ctDNA a cikin jini na majiyyaci.

"MRD wani muhimmin mahimmanci ne na kwayoyin halitta a cikin adjuvant da lokacin sa ido," in ji Farfesa Charles Swanton, MBPhD, FRCP, FMedSci, FRS, FAACR, a Cibiyar Francis Crick da Cibiyar Ciwon daji ta UCL da kuma Babban Likitan Ciwon daji na UK. "Kamar yadda muka gani a cikin binciken TRACERx, PCM yana ba da bayanan tsinkaya, zai iya taimakawa a lokuta na rashin fahimta na rediyo, kuma yana nuna girman ganewar asibiti da ƙayyadaddun bayanai."

An samo gwaje-gwajen biopsy na ruwa don zaɓin jiyya, amma don gano MRD a matakin farko fiye da hanyoyin al'ada kafin marasa lafiya su koma asibiti, dole ne fasahar ta kasance mai hankali don gano ctDNA a ƙananan matakan. Bugu da ƙari, ana buƙatar gwajin MRD tare da ƙayyadaddun ƙayyadaddun ƙayyadaddun bayanai don rage yuwuwar sakamako mai inganci na ƙarya. Gwajin PCM na amfani da fasahar ci-gaba don isa manyan matakan hankali da ƙayyadaddun ƙayyadaddun bayanai, gano ƙwayar cuta ta DNA a ƙananan matakan tattarawa a cikin jini na gefe. Nazarin tabbatarwa ya nuna sama da 99.9% hankali wajen gano ctDNA a mitar 0.008% bambance-bambancen allele.

"Muna farin ciki game da samuwar PCM a duniya, saboda wannan yanki ne mai tasowa inda muka saka hannun jari a cikin shekarar da ta gabata kuma mun yi imanin cewa yana da damar ba marasa lafiya bayanan da ake bukata don fahimtar sake dawowarsu don yaki da cutar," in ji Sean. George, Ph.D., co-kafa kuma Shugaba na Invitae.

Kowace ƙididdiga an ƙera ta ne don gano sa hannun ƙwayar cuta na musamman na majiyyaci, yana ba da damar sakamako na musamman don jagorantar yanke shawara na jiyya. Gayyatar PCM na buƙatar samfuran nama na jini da ƙari daga majiyyaci don gudanar da ƙari-al'ada gabaɗayan exome sequencing (WES). Dangane da sakamakon, Algorithm na Invitae na mallakar ya zaɓi bambance-bambancen takamaiman ƙari guda 18-50 don haɗawa akan kwamitin ctDNA na al'ada na majiyyaci. Wannan kewayon bambance-bambancen karatu yana ba da damar ma'auni na ƙima sosai da takamaiman ganowar MRD a cikin cututtukan daji waɗanda ke da ƙananan nauyin maye gurbi.

Idan an sami sakamako mai kyau na MRD a kowane lokaci a cikin tafiyar mai cutar kansa, likitan da majiyyaci na iya tattauna abubuwan da sakamakon da ya haifar da kuma mafi dacewa jiyya ko zaɓuɓɓukan gwaji na asibiti. "Wannan ilimin kwayoyin halitta yana tasiri ga masu ciwon daji a duk tsawon tafiyarsu na ciwon daji, wanda hakan ya zama babban jigon ilimin oncology," in ji George.

Gayyata tana faɗaɗa babban fayil ɗin bincike a duk duniya don ci gaba da tattara bayanai kan amfanin aikin asibiti na PCM da kuma nazarin jagororin MRD. Gayyata tana tsammanin wallafe-wallafe da yawa a wannan shekara a cikin karatun PCM ɗin sa a cikin huhu, nono, kai da wuya, da ciwace-ciwacen GI da kuma yawancin karatun da ake son farawa a farkon rabin shekara. Wadannan binciken da ake shirin yi sun hada da nazarin ƙwayar cuta (MARIA) da bincike da yawa a cikin nono da GI, ciki har da ARTEMIS, binciken da ke nazarin PCM na Invitae na musamman ga marasa lafiya da ciwon daji na pancreatic. Za a gudanar da binciken tare da haɗin gwiwar wata babbar cibiyar da ke kusa da Tokyo, Cibiyar Cibiyar Ciwon daji ta Gabas, Kashiwa, Chiba, Japan. Tarin samfurin zai fara a cikin Q2 2022.

ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:

Over the past several years, research from Invitae and the greater scientific community, including the TRACERx study led by Professor Charles Swanton at the Francis Crick Institute and University College London (UCL), and funded by Cancer Research UK, has shown that MRD monitoring can reliably identify lung cancer patients at high risk of relapse, detect post-surgical recurrence often earlier than standard imaging, assess therapy response, and potentially act as a surrogate for clinical trial endpoints.
If an MRD-positive result is obtained at any point in a cancer patient’s journey, the clinician and patient can discuss the implications of the result and the most appropriate treatment or clinical trial options.
Invitae PCM uses a novel set of personalized assays based on a patient’s tumor to detect circulating tumor DNA (ctDNA) in blood, offering the ability to perform risk stratification, response assessment to treatment and detection of cancer recurrence, based on recent studies.